Lubner David Charles — SEC Form 4 filings
SEC reporting owner CIK 1572000. 16 Form 4 filings on record with FilingPulse; latest filed 2026-08-07.
Transaction summary — filings shown
Covers all 16 filings on record, filed 2024-05-24 to 2026-08-07. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 55,555 shares, $999,990 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 6,000 shares, $450,000 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 24.
- Largest priced transaction: purchase of 55,555 shares @ $18.00 ($999,990) in Braveheart Bio, Inc., filed 2026-08-07.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | Director | 1 | 1 leg · 55,555 sh · $999,990 | — | 1 |
| Arcellx, Inc. (ACLX) | Director | 4 | — | 1 leg · 6,000 sh · $450,000 | 12 |
| Dyne Therapeutics, Inc. (DYN) | Director | 4 | — | — | 4 |
| CARGO Therapeutics, Inc. (CRGX) | Director | 3 | — | — | 3 |
| CRESCENT BIOPHARMA, INC. (CBIO) | Director | 2 | — | — | 2 |
| Vor Biopharma Inc. (VOR) | Director | 2 | — | — | 2 |
Form 4 filings — Lubner David Charles
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-07 | 4 | Braveheart Bio, Inc. (BRVE) | Purchase (P): 55,555 @ $18 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Dyne Therapeutics, Inc. (DYN) | Grant/award (A): 35,152 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | CRESCENT BIOPHARMA, INC. (CBIO) | Grant/award (A): 11,050 (derivative) @ $0 | EDGAR |
| 2026-04-28 | 4 | Dyne Therapeutics, Inc. (DYN) | Gift (G): 53,625 @ $0 | EDGAR |
| 2026-04-28 | 4 | Arcellx, Inc. (ACLX) | Code (U): 21,659 · Disposition to issuer (D): 13,626 (derivative) · Disposition to issuer (D): 59,405 (derivative) · Disposition to issuer (D): 31,794 (derivative) · Disposition to issuer (D): 61,538 (derivative) · Disposition to issuer (D): 11,459 (derivative) · +2 more | EDGAR |
| 2026-01-20 | 4 | Arcellx, Inc. (ACLX) | Option exercise (M): 6,000 @ $6.28 · Sale (S): 6,000 @ $75 · Option exercise (M): 6,000 (derivative) @ $0 | EDGAR |
| 2025-08-19 | 4 | CARGO Therapeutics, Inc. (CRGX) | Disposition to issuer (D): 25,000 (derivative) | EDGAR |
| 2025-06-23 | 4 | GLYCOMIMETICS INC (CBIO) | Grant/award (A): 9,023 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | CARGO Therapeutics, Inc. (CRGX) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Dyne Therapeutics, Inc. (DYN) | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | Arcellx, Inc. (ACLX) | Grant/award (A): 9,174 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | Vor Biopharma Inc. (VOR) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | Arcellx, Inc. (ACLX) | Grant/award (A): 8,011 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | CARGO Therapeutics, Inc. (CRGX) | Grant/award (A): 23,742 (derivative) @ $0 | EDGAR |
| 2024-05-28 | 4 | Vor Biopharma Inc. (VOR) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-05-24 | 4 | Dyne Therapeutics, Inc. (DYN) | Grant/award (A): 25,133 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1572000 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →